Close Menu

You may find more results for this query on our sister sites: GenomeWeb and 360Dx.

Home › Diagnostics › Drug Discovery & Development › Sumitomo Dainippon Pharma Doses First Patient in Dubermatinib Arm of AML Umbrella Trial

Sumitomo Dainippon Pharma Doses First Patient in Dubermatinib Arm of AML Umbrella Trial

Oct 23, 2020
|
staff reporter

NEW YORK – Sumitomo Dainippon Pharma Oncology said on Friday that it has dosed the first patient with the combination of its AXL kinase inhibitor dubermatinib (TP-0903) and the chemotherapy decitabine in the Phase Ib/II Beat AML Master Clinical Trial.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.

Dec
02
Featured Webinar

PIK3CA Mutations in Advanced Breast Cancer: The Vital Role of Tissue and Plasma Companion Diagnostics

Sponsored by
Qiagen

The Phosphoinositide 3-Kinase (PI3K) pathway is one of the most frequently altered pathways in human cancer and plays a significant role in disease progression and resistance to endocrine therapy.

What's Popular?

In Cancer

  1. Genentech, OneOncology Partner on Genomic Profiling for Personalized Cancer Care

  2. SEngine Precision Medicine IDs Potential Ovarian Cancer Treatment Combos Using Organoid Approach

    Premium

  3. FDA Accepts Invitae Premarket Approval Submission for Stratafide Companion Diagnostic

  4. Novellus, Tempus Partner to Enroll Patients in BRAF Inhibitor Clinical Trial Program

  5. Persephone Biosciences Launches Study to Assess Microbiome's Role in Cancer Treatment Response

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2020 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.